This is an analytical, longitudinal, cohort, experimental and prospective study that determines the effectiveness of treatment with interferon α2b in patients with recalcitrant warts treated in the Dermatology Outpatient Clinic during the 2022-2023 administration. The study concluded that there are significant statistical differences between the number of warts and the treatment used. The side effects of intralesional application of IFN α2b were pain (64%) and necrosis (52%). The IFN α2b group required 5 sessions for complete healing in 50% of cases. The effectiveness of the treatment was 80% for IFN α2b vs 68% for cryotherapy, with statistically significant differences.

Melany Ayala, completed her studies at the age of 22 at the Universidad Mayor de San Andrés, later she carried out her studies of  dermatology at the National Health Fund in La Paz Bolivia. Currently 28 years old, dermatologist at the Third Level Hospital in Sucre- Bolivia. Associate member of CILAD. She holds diplomas in onco-dermatology and clinical dermatology.